Danaher<\/strong> agreed to acquire medical device maker Masimo<\/strong> in a deal valued at $9.9 billion<\/strong>, marking the life sciences company\u2019s largest transaction in years as it strengthens its diagnostics capabilities.<\/p>\n\n\n\n Under the agreement, Danaher will pay $180 per share<\/strong>, representing a 38.3% premium<\/strong> to Masimo\u2019s most recent closing price. The acquisition surpasses Danaher\u2019s $5.7 billion purchase of Abcam in 2023 and signals a renewed push into higher-growth healthcare technologies.<\/p>\n\n\n\n Danaher, known for supplying tools and technologies that support pharmaceutical research and drug manufacturing, will expand further into clinical monitoring through Masimo\u2019s portfolio of non-invasive pulse oximeters.<\/p>\n\n\n\n Masimo\u2019s technology will complement Danaher\u2019s existing invasive diagnostics equipment, including Radiometer blood analysis systems. The combination positions Danaher to offer a more comprehensive suite of patient monitoring and hospital diagnostic solutions.<\/p>\n\n\n\n The deal comes as life sciences companies navigate headwinds including regulatory uncertainty around U.S. drug pricing, shifting tariff policies and reduced research funding across academic and government institutions.<\/p>\n\n\n\n Shares of Masimo<\/strong> surged more than 34% in premarket trading to $174.89 following the announcement, reflecting investor optimism over the premium valuation. Meanwhile, Danaher<\/strong> shares declined about 6%, a common reaction in large cash acquisitions where buyers absorb financing or integration risk.<\/p>\n\n\n\n Masimo currently carries a market capitalization of roughly $7 billion, compared with Danaher\u2019s valuation exceeding $150 billion.<\/p>\n\n\n\n The transaction is expected to close in the second half of 2026<\/strong>, subject to regulatory approvals and customary conditions.<\/p>\n\n\n\n Danaher projects the acquisition will add between $0.15 and $0.20<\/strong> to adjusted diluted earnings per share in the first full year following completion. By the fifth full year, the contribution is expected to rise to approximately $0.70 per share<\/strong>.<\/p>\n\n\n\n Masimo recently repositioned itself as a focused medical technology company after divesting its Sound United audio division to Samsung\u2019s Harman for $350 million. The company has also been engaged in a high-profile patent dispute with Apple<\/strong>, with a federal jury in California awarding Masimo $634 million last November over alleged infringement related to blood-oxygen reading technology.<\/p>\n\n\n\n The acquisition underscores Danaher\u2019s strategy of building scale in high-margin healthcare niches while diversifying beyond research-focused instrumentation into bedside and real-time patient monitoring technologies.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Premium Offer to Expand Diagnostics Danaher agreed to acquire medical device maker Masimo in a deal valued at $9.9 billion, marking the life sciences company\u2019s largest transaction in years as it strengthens its diagnostics capabilities. Under the agreement, Danaher will pay $180 per share, representing a 38.3% premium to Masimo\u2019s most recent closing price. The […]<\/p>\n","protected":false},"author":10772,"featured_media":13431,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[3455,3451,3459,3460,3453,3452,3454,3456,3457,3458],"class_list":{"0":"post-13430","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-danaher-acquisition","9":"tag-healthcare-diagnostics-expansion","10":"tag-hospital-diagnostic-equipment","11":"tag-life-sciences-ma","12":"tag-masimo-deal","14":"tag-medtech-earnings-growth","15":"tag-patient-monitoring-technology","16":"tag-pulse-oximeter-market","17":"tag-radiometer-systems"},"_links":{"self":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/13430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/users\/10772"}],"replies":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13430"}],"version-history":[{"count":1,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/13430\/revisions"}],"predecessor-version":[{"id":13432,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/13430\/revisions\/13432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/media\/13431"}],"wp:attachment":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Strategic Move Into Patient Monitoring<\/h2>\n\n\n\n
Market Reaction and Financial Impact<\/h2>\n\n\n\n
Earnings Outlook and Company Background<\/h2>\n\n\n\n